Carbocysteine Modifies Circulating miR-21, IL-8, sRAGE, and fAGEs Levels in Mild Acute Exacerbated COPD Patients: A Pilot Study
Patients with Chronic Obstructive Pulmonary Disease (COPD) periodically experience acute exacerbation (AECOPD). Carbocysteine represents a valid add on therapy in COPD by exerting antioxidant and anti-inflammatory activities. The in vivo effects of carbocysteine on inflammatory markers are not yet f...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-02-01
|
| Series: | Pharmaceuticals |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1424-8247/15/2/218 |
| _version_ | 1797477281579401216 |
|---|---|
| author | Maria Ferraro Serena Di Vincenzo Claudia Sangiorgi Stefania Leto Barone Sebastiano Gangemi Luigi Lanata Elisabetta Pace |
| author_facet | Maria Ferraro Serena Di Vincenzo Claudia Sangiorgi Stefania Leto Barone Sebastiano Gangemi Luigi Lanata Elisabetta Pace |
| author_sort | Maria Ferraro |
| collection | DOAJ |
| description | Patients with Chronic Obstructive Pulmonary Disease (COPD) periodically experience acute exacerbation (AECOPD). Carbocysteine represents a valid add on therapy in COPD by exerting antioxidant and anti-inflammatory activities. The in vivo effects of carbocysteine on inflammatory markers are not yet fully understood. The aims of this study were to assess: (i) miR-21, IL-8, soluble Receptor for Advanced Glycation End Products (sRAGE), and fluorescent Advanced Glycation End Products (fAGEs) in control subjects (<i>n</i> = 9), stable (<i>n</i> = 9), and AECOPD patients (<i>n</i> = 24); and (ii) whether carbocysteine modifies these markers and the functional parameters in mild AECOPD patients. Mild AECOPD patients received or not carbocysteine along with background inhalation therapy for 20 days. At the onset and at the end of the observation period, the following parameters were evaluated: FEV1, FEF25–75%, CAT questionnaire; miR-21 by Real Time PCR; IL-8 and sRAGE by ELISA; and fAGEs by spectro-fluorescence method. COPD patients showed higher levels of miR-21, IL-8, fAGEs and lower levels of sRAGE compared to that of controls. miR-21 inversely correlated with FEV1. IL-8 and fAGEs were significantly different in stable and exacerbated COPD patients. Carbocysteine improved symptoms, FEV1 and FEF25–75%, increased sRAGE, and reduced miR-21, IL-8, and fAGEs in mild AECOPD patients. The present study provides compelling evidence that carbocysteine may help to manage mild AECOPD by downregulating some parameters of systemic inflammation. |
| first_indexed | 2024-03-09T21:16:20Z |
| format | Article |
| id | doaj.art-d2efd8129c3b4788b27948ae3206c250 |
| institution | Directory Open Access Journal |
| issn | 1424-8247 |
| language | English |
| last_indexed | 2024-03-09T21:16:20Z |
| publishDate | 2022-02-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Pharmaceuticals |
| spelling | doaj.art-d2efd8129c3b4788b27948ae3206c2502023-11-23T21:34:55ZengMDPI AGPharmaceuticals1424-82472022-02-0115221810.3390/ph15020218Carbocysteine Modifies Circulating miR-21, IL-8, sRAGE, and fAGEs Levels in Mild Acute Exacerbated COPD Patients: A Pilot StudyMaria Ferraro0Serena Di Vincenzo1Claudia Sangiorgi2Stefania Leto Barone3Sebastiano Gangemi4Luigi Lanata5Elisabetta Pace6Institute for Biomedical Research and Innovation (IRIB)—Consiglio Nazionale delle Ricerche, 90146 Palermo, ItalyInstitute for Biomedical Research and Innovation (IRIB)—Consiglio Nazionale delle Ricerche, 90146 Palermo, ItalyInstitute for Biomedical Research and Innovation (IRIB)—Consiglio Nazionale delle Ricerche, 90146 Palermo, ItalyCasa di Cura Orestano, 90138 Palermo, ItalyDepartment of Clinical and Experimental Medicine, School and Operative Unit of Allergy and Clinical Immunology, University of Messina, 98125 Messina, ItalyDompè Medical Affair, 20122 Milan, ItalyInstitute for Biomedical Research and Innovation (IRIB)—Consiglio Nazionale delle Ricerche, 90146 Palermo, ItalyPatients with Chronic Obstructive Pulmonary Disease (COPD) periodically experience acute exacerbation (AECOPD). Carbocysteine represents a valid add on therapy in COPD by exerting antioxidant and anti-inflammatory activities. The in vivo effects of carbocysteine on inflammatory markers are not yet fully understood. The aims of this study were to assess: (i) miR-21, IL-8, soluble Receptor for Advanced Glycation End Products (sRAGE), and fluorescent Advanced Glycation End Products (fAGEs) in control subjects (<i>n</i> = 9), stable (<i>n</i> = 9), and AECOPD patients (<i>n</i> = 24); and (ii) whether carbocysteine modifies these markers and the functional parameters in mild AECOPD patients. Mild AECOPD patients received or not carbocysteine along with background inhalation therapy for 20 days. At the onset and at the end of the observation period, the following parameters were evaluated: FEV1, FEF25–75%, CAT questionnaire; miR-21 by Real Time PCR; IL-8 and sRAGE by ELISA; and fAGEs by spectro-fluorescence method. COPD patients showed higher levels of miR-21, IL-8, fAGEs and lower levels of sRAGE compared to that of controls. miR-21 inversely correlated with FEV1. IL-8 and fAGEs were significantly different in stable and exacerbated COPD patients. Carbocysteine improved symptoms, FEV1 and FEF25–75%, increased sRAGE, and reduced miR-21, IL-8, and fAGEs in mild AECOPD patients. The present study provides compelling evidence that carbocysteine may help to manage mild AECOPD by downregulating some parameters of systemic inflammation.https://www.mdpi.com/1424-8247/15/2/218respiratory pharmacologyinflammationantioxidantsCOPDexacerbationscarbocysteine |
| spellingShingle | Maria Ferraro Serena Di Vincenzo Claudia Sangiorgi Stefania Leto Barone Sebastiano Gangemi Luigi Lanata Elisabetta Pace Carbocysteine Modifies Circulating miR-21, IL-8, sRAGE, and fAGEs Levels in Mild Acute Exacerbated COPD Patients: A Pilot Study Pharmaceuticals respiratory pharmacology inflammation antioxidants COPD exacerbations carbocysteine |
| title | Carbocysteine Modifies Circulating miR-21, IL-8, sRAGE, and fAGEs Levels in Mild Acute Exacerbated COPD Patients: A Pilot Study |
| title_full | Carbocysteine Modifies Circulating miR-21, IL-8, sRAGE, and fAGEs Levels in Mild Acute Exacerbated COPD Patients: A Pilot Study |
| title_fullStr | Carbocysteine Modifies Circulating miR-21, IL-8, sRAGE, and fAGEs Levels in Mild Acute Exacerbated COPD Patients: A Pilot Study |
| title_full_unstemmed | Carbocysteine Modifies Circulating miR-21, IL-8, sRAGE, and fAGEs Levels in Mild Acute Exacerbated COPD Patients: A Pilot Study |
| title_short | Carbocysteine Modifies Circulating miR-21, IL-8, sRAGE, and fAGEs Levels in Mild Acute Exacerbated COPD Patients: A Pilot Study |
| title_sort | carbocysteine modifies circulating mir 21 il 8 srage and fages levels in mild acute exacerbated copd patients a pilot study |
| topic | respiratory pharmacology inflammation antioxidants COPD exacerbations carbocysteine |
| url | https://www.mdpi.com/1424-8247/15/2/218 |
| work_keys_str_mv | AT mariaferraro carbocysteinemodifiescirculatingmir21il8srageandfageslevelsinmildacuteexacerbatedcopdpatientsapilotstudy AT serenadivincenzo carbocysteinemodifiescirculatingmir21il8srageandfageslevelsinmildacuteexacerbatedcopdpatientsapilotstudy AT claudiasangiorgi carbocysteinemodifiescirculatingmir21il8srageandfageslevelsinmildacuteexacerbatedcopdpatientsapilotstudy AT stefanialetobarone carbocysteinemodifiescirculatingmir21il8srageandfageslevelsinmildacuteexacerbatedcopdpatientsapilotstudy AT sebastianogangemi carbocysteinemodifiescirculatingmir21il8srageandfageslevelsinmildacuteexacerbatedcopdpatientsapilotstudy AT luigilanata carbocysteinemodifiescirculatingmir21il8srageandfageslevelsinmildacuteexacerbatedcopdpatientsapilotstudy AT elisabettapace carbocysteinemodifiescirculatingmir21il8srageandfageslevelsinmildacuteexacerbatedcopdpatientsapilotstudy |